Pivotal Trial: TransCon CNP Shows Continued 2-Year Improvements in Achondroplasia, Well-Tolerated
ASND sits 63% above its 52-week low of $160.86.
Summary
Ascendis Pharma announced positive Week 104 (two-year) data from its pivotal ApproaCH trial for TransCon CNP in children with achondroplasia. The drug demonstrated continued improvements in lower extremity alignment, with an average tibial-femoral angle (TFA) decreasing by 2.2 degrees over two years in all treated children, and was generally well-tolerated with a low rate of adverse events. This follows earlier positive Week 52 data from the Phase 2 COACH trial for TransCon CNP reported in April. The long-term efficacy and safety data from a pivotal trial significantly de-risks TransCon CNP, strengthening its profile for potential regulatory approval and commercial success in this rare disease.
At the time of this announcement, ASND was trading at $261.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.4B. The 52-week trading range was $160.86 to $271.89. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.